Angiotensin receptor–neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs. (1st January 2017)

• Record Type: Journal Article
• Authors: Gori, Mauro; Volterrani, Maurizio; Piepoli, Massimo; Senni, Michele
• Is Part Of: International journal of cardiology. Volume 226(2017)
• Page Start: 136
• Page End: 140
• Publication Date: 2017-01-01
• Subjects: Angiotensin receptor–neprilysin inhibitor -- ARNi -- Heart failure -- LCZ696; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2016.06.083
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Sacubritil ∗ valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor–neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies. Highlights: LCZ696 is a combination drug acting as angiotensin receptor-neprilysin inhibitor In a phase 2 trial in HFpEF, LCZ696 compared to valsartan has shown superiority on surrogated outcomes According to PARADIGM-HF design, LCZ696 may replace ACEi/ARB therapy in symptomatic HFrEF patients Whether LCZ696 will replace ACEi/ARB in newly diagnosed and in HF hospitalized patients remains unclear Morbidity and mortality benefit with LCZ696 in HFpEF is being tested in the ongoing PARAGON trial